Treatment of Impetigo on Hand Lesions

First-Line Treatment

• The American Academy of Pediatrics recommends switching to oral antibiotics if the impetigo is extensive, not responding to topical therapy after 3-5 days, or associated with systemic symptoms 1

Oral Antibiotic Options

• For presumed methicillin-susceptible S. aureus (MSSA), the Infectious Diseases Society of America recommends dicloxacillin 250 mg four times daily for adults, or cephalexin 250-500 mg four times daily for adults 1
• If MRSA is suspected or confirmed, the Clinical Infectious Diseases society recommends clindamycin 300-450 mg three times daily for adults, or trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily for adults 2, 3

Important Considerations

• The Infectious Diseases Society of America notes that penicillin alone is not effective for impetigo as it lacks adequate coverage against S. aureus 1
• The Clinical Infectious Diseases society recommends obtaining cultures from lesions if there is treatment failure, MRSA is suspected, or in cases of recurrent infections 2
• The American Academy of Pediatrics recommends a duration of therapy of 5-7 days for topical treatment and 5-10 days for oral antibiotics 1, 2

Prevention of Spread

• The Clinical Infectious Diseases society recommends keeping lesions covered with clean, dry bandages, maintaining good personal hygiene with regular handwashing, and avoiding sharing personal items that contact the skin 2

Special Populations

• The American Academy of Pediatrics recommends avoiding tetracyclines in children under 8 years, and considering cephalexin as a safe alternative for pregnant patients 1, 2, 3

Treatment of Impetigo

Initial Treatment Selection

• The Infectious Diseases Society of America recommends mupirocin 2% ointment applied three times daily as the most effective topical agent for impetigo caused by S. aureus and S. pyogenes 4
• Bacitracin and neomycin are considerably less effective and should not be used for impetigo treatment, according to the Clinical Infectious Diseases guidelines 4
• Lesions on the face, eyelid, or mouth require oral antibiotics, as indicated by the Clinical Infectious Diseases guidelines 4
• Failure to respond to topical therapy after 3-5 days, need to limit spread to others, and systemic symptoms present are indications for oral antibiotics, as recommended by the Clinical Infectious Diseases guidelines 4
• Clindamycin is the preferred alternative for penicillin-allergic patients, as stated in the Clinical Infectious Diseases guidelines 4

Clindamycin Cream for Impetigo

Inappropriate Use of Clindamycin Cream

• The American Academy of Dermatology states that clindamycin cream lacks FDA indication for impetigo, as it is specifically approved for topical treatment of acne vulgaris, not superficial bacterial skin infections 5
• The Centers for Disease Control and Prevention notes that topical clindamycin for acne has minimal systemic absorption (approximately 4% bioavailability), which is insufficient to treat bacterial skin infections like impetigo 6
• The American Academy of Dermatology recommends that clindamycin cream should not be used for impetigo treatment, as the formulation is not designed or tested for this purpose 5

Critical Distinction: Oral vs. Topical Clindamycin

• The Infectious Diseases Society of America implies that oral clindamycin is an appropriate systemic antibiotic for impetigo, particularly when MRSA is suspected, but notes that topical clindamycin cream is not interchangeable with oral clindamycin for treating bacterial skin infections 5

Treatment of Impetigo

Initial Assessment and Treatment Selection

• For limited impetigo, topical mupirocin 2% ointment applied three times daily for 5-7 days is the first-line treatment, while extensive disease, systemic symptoms, or lesions on the face/mouth require oral antibiotics such as cephalexin or dicloxacillin for 7 days, as recommended by the Infectious Diseases Society of America 7
• Patient can comply with three-times-daily application of topical therapy, which is appropriate for limited disease 7
• Systemic symptoms are present, requiring oral antibiotics, as suggested by the Clinical Infectious Diseases guidelines 7

Oral Antibiotic Selection

• Duration of oral antibiotic treatment is 7 days for presumed methicillin-susceptible S. aureus (MSSA) and when MRSA is suspected or confirmed, according to the Clinical Infectious Diseases guidelines 7

Special Populations and Allergy Considerations

• Avoid cephalosporins if type 1 hypersensitivity (anaphylaxis/hives) to β-lactams in penicillin-allergic patients, as recommended by the Clinical Infectious Diseases guidelines 7

Immunocompromised Patients

• Lower threshold for oral antibiotics is required for immunocompromised patients, who also need to be monitored closely for treatment failure or deeper infection, as suggested by the Clinical Infectious Diseases guidelines 7
• Monitor closely for treatment failure or deeper infection in immunocompromised patients, and consider longer treatment duration based on clinical response, according to the Clinical Infectious Diseases guidelines 7

Culture Indications

• Cultures are not routinely necessary for typical cases of limited impetigo, but may be required for immunocompromised hosts, as recommended by the Clinical Infectious Diseases guidelines 7

Treatment During Outbreaks

• Systemic antimicrobials should be used during outbreaks of poststreptococcal glomerulonephritis to help eliminate nephritogenic strains of S. pyogenes from the community, as suggested by the Clinical Infectious Diseases guidelines 7

Monitoring and Follow-up

• If no improvement occurs by 3-5 days of appropriate therapy, reassess for MRSA infection requiring alternative antibiotics, as recommended by the Clinical Infectious Diseases guidelines 7
• Deeper or more complex infection than initially estimated, non-compliance with therapy, or antibiotic resistance should be considered if no improvement occurs by 3-5 days of appropriate therapy, according to the Clinical Infectious Diseases guidelines 8

Impetigo Treatment Guidelines

Initial Assessment and Treatment Selection

• The American Academy of Pediatrics recommends that oral antibiotics should be used when there is no improvement after 3-5 days of topical therapy, or when there is a need to limit the spread to others, such as during outbreaks 9
• The American Academy of Pediatrics suggests that athletes should be excluded from participation until 24 hours after initiation of effective antimicrobial therapy, and skin lesions must be covered with clean, dry bandages 9

Prevention and Infection Control

• The American Academy of Pediatrics recommends that during outbreaks, systemic antimicrobials should be used to help eliminate nephritogenic strains of S. pyogenes from the community, and consider decolonization strategies using topical nasal mupirocin therapy for S. aureus carriers 9
• The American Academy of Pediatrics advises that for athletes and organized sports, good personal hygiene with regular handwashing should be maintained, and personal items that contact the skin should not be shared 9

Infection Control and Outbreak Management for Impetigo

Personal Hygiene Measures

• Avoid sharing personal items that contact the skin (e.g., towels, equipment) to reduce transmission of impetigo. 10

Indications for Obtaining Cultures

• Perform bacterial cultures when impetigo recurs, to identify possible resistant pathogens and guide therapy. 10

Outbreak Response

• Use systemic antimicrobial therapy during community outbreaks to eliminate nephritogenic Streptococcus pyogenes strains. 10
• Involve public‑health authorities in outbreak management to coordinate control measures and prevent further spread. 10